Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 9421

BillFederalHouseIn Committee
To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
About This Bill
Committee
Latest Action · June 24, 2026
Referred to the House Committee on Energy and Commerce.
Congress
119th (2025–2027)
Introduced
June 24, 2026
Cosponsors (9)
0D 9R
View PDF ↗

Summary

Highlight any text to annotate
The Ban Abortion by Mail Act would prohibit doctors certified to prescribe mifepristone, a medication used for abortion, from dispensing it through mail or telehealth without an in-person visit with the patient. The bill also requires that providers have a medical license in the same state where the patient resides. Any provider who violates these requirements would lose their certification to prescribe the drug for at least two years. The legislation applies to all providers certified under the FDA's Risk Evaluation and Mitigation Strategies (REMS) program for mifepristone. The bill requires the Secretary of Health and Human Services to submit annual reports to Congress listing providers who lose their certification due to violations of these requirements or unsafe prescribing practices.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.